IpilimumabIpilimumab is a human monoclonal antibody being developed by Bristol-Myers Squibb and Medarex. It is intended to be used as a drug to activate the immune system. Ipilimumab is undergoing clinical trials for the treatment of melanoma, non small cell lung cancer, small cell lung cancer and metastatic hormone-refractory prostate cancer. Ipilimumab is an experimental melanoma drug has been found to significantly improve survival in a major study of people with very advanced disease. Dr. Lynn Schucher of the Abramson Cancer Center in Pennsylvania said: "We have not had any therapy that has prolonged survival, until now." The Food and Drug Administration (FDA) has pledged a quick review, and doctors think the drug could be available by the end of this year. Reuters has just reported on a clinical trial presented at the American Society of Clinical Oncology. The study showed an improvement in median survival from 6 months to 10 in patients with advanced melanomas, over treatment with an experimental vaccine called GP-100(total n=676). Additionally, one year survival was 25% in patients treated with the vaccine, versus 46% in those treated with Ipilimumab, and 44% for those receiving both. The success with Ipilimumab may raise hopes for Pfizer Inc's tremelimumab, another monoclonal antibody that targets CTLA-4. Two years ago, that drug failed in a large study comparing it to chemotherapy. Earlier this year, Pfizer signed a deal to co-develop the drug using a biomarker to pick patients most likely to respond. +++++++++++One patient's video journey from deciding on prostate cancer surgery, the robotic prostatectomy, da Vinci® Prostatectomy is more accurately a robot-assisted, minimally invasive surgery and recovery from surgery. |